Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04192344 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
A Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 276
- Enrollment target
- 17
- Study locations
NCT04192344: Recruiting Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor, sponsored by Abbisko Therapeutics Co.
NCT04192344 is a Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 276 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (83% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04192344, a Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 276 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Primary Outcome
DLT(dose-limiting toxicity)
Conditions Studied
Interventions
- DRUG ABSK021
Study Locations (17)
Henan
- Henan Cancer Hospital - Zhengzhou
- The First Affiliated Hospital of Zhengzhou Universtity - Zhengzhou
Jiangsu
- Jiangsu Province Hospital - Nanjing
- Nanjing Drum Tower Hospital - Nanjing
Shanghai Municipality
- Huashan Hospital of Fudan University - Shanghai
- Shanghai Sixth People's Hospital - Shanghai
California
- Precision NextGen Oncology - Beverly Hills
Colorado
- SCRI at HealthOne - Denver
Georgia
- The Winship Cancer Institute of Emory University - Atlanta
Texas
- MD Anderson Cancer Center - Houston
Beijing Municipality
- Beijing Jishuitan Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2020-01-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT04192344 shows while recruiting
NCT04192344 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ABSK021 is the first listed.
NCT04192344 lists 17 locations in 14 states (Henan, Jiangsu, Shanghai Municipality).
Frequently Asked Questions
What is clinical trial NCT04192344 about?
NCT04192344 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor". This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
What is the current status of trial NCT04192344?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2020-01-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04192344 study?
This clinical trial studies the following conditions: Neoplasms, Tenosynovial Giant Cell Tumor.
What interventions are being tested in trial NCT04192344?
The interventions under investigation include: ABSK021 (DRUG).
Who is sponsoring clinical trial NCT04192344?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04192344 being conducted?
This trial has 17 study locations across California, Colorado, Georgia, Texas, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04192344's enrollment target sits among peer trials
276 35th of 158 higher than 124 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- NCT05611931 · 276 participants · Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI